Plus   Neg

Agora Q4 Attributable Loss Narrows; Stock Plunges

Agora Inc. (API) reported that its net loss attributable to ordinary shareholders for the fourth-quarter narrowed to $6.18 million or $0.06 per ADS, from $21.57 million or $0.73 per ADS in the same period last year, which was primarily due to accretion of preferred shares to redemption value.

But, quarterly net loss widened to $6.2 million, from of $2.3 million in the previous year.

API closed Monday regular trading at $78.95, down $19.13 or 19.50%. In the after hours trade, the stock further dropped $6.25 or 7.92%.

Non-GAAP net loss for the quarter was $3.2 million, compared to the non-GAAP net loss of $1.5 million in the fourth quarter of 2019.

Active Customers as of December 31, 2020 were 2,095, an increase of 101.2% from 1,041 as of December 31, 2019.

Total revenues for the fourth-quarter were $33.3 million, an increase of 74.1% from $19.1 million in the same period last year, primarily due to increased usage of our video and voice products as a result of our business expansion.

Analysts polled by Thomson Reuters expected the company to report a loss of $0.07 per share and revenues of $31.04 million for the fourth-quarter. Analysts' estimates typically exclude special items.

Agora said that Siming Tao, Agora's senior vice president of products, is resigning from his senior vice president position at Agora for personal reason, effective from February 28, 2021.

Agora announced that Stanley Wei will join the company as its chief strategy officer, responsible for overall strategic planning, investments and global expansion.

Agora expects that total revenues for the fiscal year ending December 31, 2021 to be between $178 million and $182 million. Analysts expect revenue of $169.26 million for fiscal year 2021.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Johnson & Johnson's (JNJ) Covid-19 vaccine is expected to be back on track as early as this weekend as a decision is expected after the advisory panel meeting of the U.S. Centers for Disease Control and Prevention (CDC) slated on April 23, according to Dr. Anthony Fauci, the chief medical adviser to President Joe Biden. MK-4482, the experimental antiviral drug for COVID-19, showed promise to prevent and treat SARS-CoV-2 infection in hamster study, according to the scientists of National Institutes of Health or NIH. The drug significantly decreased levels of virus and disease damage in the lungs of hamsters treated for SARS-CoV-2 infection. MK-4482, delivered orally, is now in Phase 2 and 3 human clinical studies. Beverages giant Coca-Cola reported a 19 percent decline in profit for the second quarter from last year as a revenue growth of 5 percent and improved margins were offset by higher income taxes and interest expense. However, adjusted earnings per share and revenues topped analysts' expectations. The company also maintained its adjusted earnings and organic revenue growth outlook for fiscal 2021.
Follow RTT